CN1139592C - 喜树碱衍生物，其制备用途以及中间体 - Google Patents

喜树碱衍生物，其制备用途以及中间体 Download PDF

Info

Publication number
CN1139592C
CN1139592C CNB008047804A CN00804780A CN1139592C CN 1139592 C CN1139592 C CN 1139592C CN B008047804 A CNB008047804 A CN B008047804A CN 00804780 A CN00804780 A CN 00804780A CN 1139592 C CN1139592 C CN 1139592C
Authority
CN
China
Prior art keywords
compound
group
formula
camptothecin
iminomethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008047804A
Other languages
English (en)
Chinese (zh)
Other versions
CN1343209A (zh
Inventor
S
S·潘科
L·默里尼
��˹��ŵ��
F·祖尼诺
�����ɵ�
P·卡米纳迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Publication of CN1343209A publication Critical patent/CN1343209A/zh
Application granted granted Critical
Publication of CN1139592C publication Critical patent/CN1139592C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB008047804A 1999-03-09 2000-03-08 喜树碱衍生物，其制备用途以及中间体 Expired - Fee Related CN1139592C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99830124.6 1999-03-09
EP99830124A EP1044977B1 (en) 1999-03-09 1999-03-09 Camptothecin derivatives having antitumor activity

Publications (2)

Publication Number Publication Date
CN1343209A CN1343209A (zh) 2002-04-03
CN1139592C true CN1139592C (zh) 2004-02-25

Family

ID=8243303

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008047804A Expired - Fee Related CN1139592C (zh) 1999-03-09 2000-03-08 喜树碱衍生物，其制备用途以及中间体

Country Status (38)

Country Link
US (2) US6242457B1 (enExample)
EP (1) EP1044977B1 (enExample)
JP (1) JP4610743B2 (enExample)
KR (1) KR100702085B1 (enExample)
CN (1) CN1139592C (enExample)
AR (1) AR022860A1 (enExample)
AT (1) ATE216998T1 (enExample)
AU (1) AU774174B2 (enExample)
BG (1) BG65032B1 (enExample)
BR (1) BR0008840B1 (enExample)
CA (1) CA2362760C (enExample)
CO (1) CO5180590A1 (enExample)
CZ (1) CZ304465B6 (enExample)
DE (1) DE69901379T2 (enExample)
DK (1) DK1044977T3 (enExample)
EA (1) EA003605B1 (enExample)
EE (1) EE04679B1 (enExample)
EG (1) EG23999A (enExample)
ES (1) ES2175919T3 (enExample)
HR (1) HRP20010667B1 (enExample)
HU (1) HU229506B1 (enExample)
IL (2) IL144958A0 (enExample)
IS (1) IS2003B (enExample)
ME (2) MEP4008A (enExample)
MX (1) MXPA01009081A (enExample)
NO (1) NO328363B1 (enExample)
NZ (1) NZ513393A (enExample)
PE (1) PE20001485A1 (enExample)
PL (1) PL222208B1 (enExample)
PT (1) PT1044977E (enExample)
RS (1) RS50405B (enExample)
SI (1) SI1044977T1 (enExample)
SK (1) SK287561B6 (enExample)
TN (1) TNSN00045A1 (enExample)
TR (1) TR200102603T2 (enExample)
TW (1) TWI272272B (enExample)
WO (1) WO2000053607A1 (enExample)
ZA (1) ZA200107408B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140198B1 (en) 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
FR2794123B1 (fr) * 1999-05-28 2001-07-27 Aventis Pharma Sa Preparation de derives de la camptothecine et de la nothapodytine
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US20040029906A1 (en) * 2001-07-31 2004-02-12 Michael Christman Inhibitors of dna polymerase sigma
MXPA04001828A (es) * 2001-08-27 2005-03-07 Meditech Res Ltd Protocolos terapeuticos mejorados.
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
ITRM20020306A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
ITRM20020305A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Camptotecine con anello lattonico modificato.
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
ITRM20030344A1 (it) * 2003-07-14 2005-01-15 Ist Naz Stud Cura Dei Tumori 7-n-poliamminoalchil(ossi)imminometilcamptotecine recanti gruppi protettivi.
WO2005092302A2 (en) * 2004-03-26 2005-10-06 Novartis Ag Use of camptothecin derivates for the treatment of proliferative diseases in a fixed dosing regimen
US20070207149A1 (en) 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
ITRM20040241A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 20 con antagonisti delle integrine.
ITRM20040242A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori "7-t-butossiimminometilcamptotecina coniugata in posizione 20 con antagonisti delle integrine.
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
CN100334089C (zh) * 2004-07-21 2007-08-29 王洋 一种9－硝基喜树碱的生产方法
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
ES2374828T3 (es) * 2004-12-15 2012-02-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combinaciones de agentes terapéuticos para el tratamiento del cáncer.
ES2395930T3 (es) 2004-12-21 2013-02-18 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Procedimiento estereoselectivo y formas cristalinas de una camptotecina
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
CA2612949C (en) 2005-07-14 2015-04-28 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
US20080213385A1 (en) * 2005-08-10 2008-09-04 Oskar Kalb Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin
EP1922077A4 (en) * 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd THERAPEUTIC COMPOSITIONS WITH HYALURON AND THERAPEUTIC ANTIBODIES AND TREATMENT PROCEDURES
SI1962850T1 (sl) * 2005-12-21 2012-06-29 Sigma Tau Ind Farmaceuti Zdravljenje tumorjev, odpornih proti zdravilom
EP1989212B1 (en) * 2006-02-17 2013-06-19 Cascade Prodrug Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
EP1998809B1 (en) 2006-03-30 2014-06-25 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
AU2008210511A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
US8853233B2 (en) * 2007-02-13 2014-10-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
CA2694389C (en) * 2007-08-01 2016-01-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A Treatment of pediatric tumors
EP2096113A1 (en) 2008-02-05 2009-09-02 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. 9-substituted camptothecin derivatives as antitumor compounds
TWI482621B (zh) 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
US10517961B2 (en) 2015-09-25 2019-12-31 ZY Therapeutics, Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
CN122497675A (zh) * 2024-06-05 2026-07-31 荣昌生物制药(烟台)股份有限公司 一种喜树碱类化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
ZA928771B (en) * 1991-11-15 1993-09-08 Smithkline Beecham Corp Combination chemotherapy
US5614529A (en) * 1994-09-22 1997-03-25 Research Triangle Institute Inhibition of plasmodia parasites by camptothecin compounds
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
GB9512670D0 (en) * 1995-06-21 1995-08-23 Sod Conseils Rech Applic Camptothecin analogues
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
DE69728152T2 (de) * 1996-08-19 2004-08-05 Bionumerik Pharmaceuticals, Inc., San Antonio Hoch-lipophile campothecin-derivate

Also Published As

Publication number Publication date
KR20010102519A (ko) 2001-11-15
PL355094A1 (en) 2004-03-22
PL222208B1 (pl) 2016-07-29
NO20014128L (no) 2001-08-24
EE200100466A (et) 2002-12-16
HRP20010667B1 (en) 2003-06-30
CA2362760A1 (en) 2000-09-14
ATE216998T1 (de) 2002-05-15
BR0008840A (pt) 2002-01-08
CN1343209A (zh) 2002-04-03
MEP4008A (xx) 2010-02-10
DK1044977T3 (da) 2002-07-08
JP4610743B2 (ja) 2011-01-12
IL144958A (en) 2009-08-03
HRP20010667A2 (en) 2002-08-31
NO328363B1 (no) 2010-02-01
PT1044977E (pt) 2002-09-30
HU229506B1 (en) 2014-01-28
HUP0200210A3 (en) 2004-03-29
CO5180590A1 (es) 2002-07-30
US6589939B2 (en) 2003-07-08
MXPA01009081A (es) 2002-08-30
AU3160400A (en) 2000-09-28
RS50405B (sr) 2009-12-31
JP2002539128A (ja) 2002-11-19
DE69901379T2 (de) 2002-11-07
EG23999A (en) 2008-03-19
AR022860A1 (es) 2002-09-04
US20010008939A1 (en) 2001-07-19
KR100702085B1 (ko) 2007-04-02
ES2175919T3 (es) 2002-11-16
SK11642001A3 (sk) 2002-01-07
SK287561B6 (sk) 2011-02-04
CZ304465B6 (cs) 2014-05-21
ZA200107408B (en) 2002-05-29
BR0008840B1 (pt) 2011-12-27
NZ513393A (en) 2003-04-29
EE04679B1 (et) 2006-08-15
TNSN00045A1 (fr) 2005-11-10
IS2003B (is) 2005-04-15
IS6031A (is) 2001-07-31
ME00017B (me) 2010-06-10
HK1031222A1 (en) 2001-06-08
CZ20013077A3 (cs) 2002-01-16
EP1044977B1 (en) 2002-05-02
TR200102603T2 (tr) 2002-01-21
EA003605B1 (ru) 2003-06-26
NO20014128D0 (no) 2001-08-24
PE20001485A1 (es) 2000-12-07
WO2000053607A1 (en) 2000-09-14
BG105810A (en) 2002-06-28
US6242457B1 (en) 2001-06-05
YU64301A (sh) 2005-07-19
DE69901379D1 (de) 2002-06-06
BG65032B1 (bg) 2006-12-29
EA200100954A1 (ru) 2002-04-25
HUP0200210A2 (hu) 2002-05-29
AU774174B2 (en) 2004-06-17
EP1044977A1 (en) 2000-10-18
TWI272272B (en) 2007-02-01
SI1044977T1 (en) 2002-08-31
CA2362760C (en) 2009-08-18
IL144958A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
CN1343209A (zh) 具有抗肿瘤活性的喜树碱
CN1122668C (zh) 环氧噻酮衍生物，其制备方法及其药物组合物
CN1158614A (zh) 新型化合物及其制法和抗肿瘤剂
CN1511151A (zh) 3-喹啉-2(1h)-亚基二氢吲哚-2-酮衍生物
CN1863795A (zh) P－糖蛋白抑制剂,其制备方法和包括该抑制剂的药物组合物
CN1168139A (zh) 喜树碱衍生物及其制备方法
CN1509291A (zh) 噁唑并嘧啶和呋喃并嘧啶化合物以及它们作为抗肿瘤药物的用途
CN1812986A (zh) 呋咱并苯并咪唑类化合物
CN1715283A (zh) 新藤黄酸衍生物及其制备方法和用途
CN1205704A (zh) 2,7－取代的八氢－吡咯并[1,2－a]吡嗪衍生物
CN1842517A (zh) 芴衍生物
CN1302804A (zh) 二氢呋喃并[3,4－b]喹啉－1－酮类新化合物、其制备方法和含有这些化合物的药物组合物
CN1656100A (zh) 带有修饰的内酯环的喜树碱
CN1195757C (zh) 光学纯的喜树碱类似物及组合物和用途
CN100338066C (zh) 六环化合物
CN1304306A (zh) 用于抑制mrp1的方法
CN1086188C (zh) 新颖的菲啶鎓衍生物
CN1296408A (zh) 抑制mrp1的方法
CN1147491C (zh) 新的吖啶羧酸酯化合物、其制备方法及其药物组合物
CN1101818C (zh) 20(s)－喜树碱的水溶性C－环类似物,制备方法和用途
CN1761668A (zh) 具有抗肿瘤活性的喜树碱的7－亚氨基衍生物
CN1297556C (zh) 苯并[b]色烯并－萘啶－7－酮和吡喃并[2＇,3＇:7,8]喹啉并[2,3－b]喹喔啉－7－酮化合物、其制备方法及药用组合物
CN1187352C (zh) 菲洛啉－7－酮衍生物以及它们的治疗用途
CN1064486A (zh) 嗪并吲哚化合物
CN1635998A (zh) 三环止痛药

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CI01 Publication of corrected invention patent application

Correction item: Denomination of Invention

Correct: Camptothecin derivatives, process for their preparation and their use and intermediates

False: Camptothecin derivatives, their preparation, use and intermediates

Number: 8

Page: 381

Volume: 20

CI03 Correction of invention patent

Correction item: Denomination of Invention

Correct: Camptothecin derivatives, process for their preparation and their use and intermediates

False: Camptothecin derivatives, their preparation, use and intermediates

Number: 8

Page: The title page

Volume: 20

COR Change of bibliographic data

Free format text: CORRECT: INVENTION NAME; FROM: CAMPTOTHECIN DERIVATIVES, PREPARING USE AND INTERMEDIATE BODY TO: CAMPTOTHECIN DERIVATIVES, PREPARATION METHOD AND THE USE AND INTERMEDIATE BODY

ERR Gazette correction

Free format text: CORRECT: INVENTION NAME; FROM: CAMPTOTHECIN DERIVATIVES, PREPARING USE AND INTERMEDIATE BODY TO: CAMPTOTHECIN DERIVATIVES, PREPARATION METHOD AND THE USE AND INTERMEDIATE BODY

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040225

Termination date: 20180308